Olema Pharmaceuticals, Inc. Nonoperating Income (Expense) in USD from 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Olema Pharmaceuticals, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from 2019 to Q3 2025.
  • Olema Pharmaceuticals, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2025 was $3.66M, a 19.4% increase year-over-year.
  • Olema Pharmaceuticals, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2025 was $15.4M, a 16.6% increase year-over-year.
  • Olema Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2024 was $12.8M, a 53.9% increase from 2023.
  • Olema Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2023 was $8.31M, a 277% increase from 2022.
  • Olema Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2022 was $2.2M, a 457% increase from 2021.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)

Olema Pharmaceuticals, Inc. Quarterly Nonoperating Income (Expense) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $15.4M $3.66M +$594K +19.4% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-10
Q2 2025 $14.8M $4.08M +$932K +29.6% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-11
Q1 2025 $13.9M $4.48M +$1.12M +33.1% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-13
Q4 2024 $12.8M $3.2M -$443K -12.2% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-18
Q3 2024 $13.2M $3.07M +$1.23M +66.6% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-10
Q2 2024 $12M $3.15M +$1.64M +109% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-11
Q1 2024 $10.4M $3.37M +$2.05M +156% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-13
Q4 2023 $8.31M $3.64M +$2.6M +250% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-18
Q3 2023 $5.7M $1.84M +$1.34M +267% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $4.36M $1.51M +$1.07M +246% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $3.29M $1.32M +$1.09M +488% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $2.2M $1.04M +$921K +774% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-11
Q3 2022 $1.28M $502K +$453K +924% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $827K $435K +$319K +275% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $508K $224K +$113K +102% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $395K $119K Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 $49K +$25K +104% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $116K +$83K +252% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $111K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q3 2020 $24K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $33K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10

Olema Pharmaceuticals, Inc. Annual Nonoperating Income (Expense) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $12.8M +$4.48M +53.9% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-18
2023 $8.31M +$6.11M +277% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-18
2022 $2.2M +$1.81M +457% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-11
2021 $395K +$988K Jan 1, 2021 Dec 31, 2021 10-K 2023-03-09
2020 -$593K -$600K -8571% Jan 1, 2020 Dec 31, 2020 10-K 2022-02-28
2019 $7K Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.